UNITED STATES SECURITIES AND EXCHANGE COMMISSION 10 April 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioLineRx Ltd.

File No. 1-35223 -- CF# 34814

BioLineRx Ltd. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 23, 2017.

Based on representations by BioLineRx Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| Exhibit 4.42 | through March 7, 2020 |
|--------------|------------------------|
| Exhibit 4.46 | through March 22, 2020 |
| Exhibit 4.47 | through March 22, 2020 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary